Halozyme Therapeutics, Inc.
HALO
$49.20
-$1.04-2.06%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Net Income | 118.10M | 137.01M | 137.01M | 93.25M | 76.82M |
| Total Depreciation and Amortization | 20.45M | 20.42M | 20.36M | 20.33M | 20.21M |
| Total Amortization of Deferred Charges | 1.85M | 1.84M | 1.84M | 1.84M | 1.83M |
| Total Other Non-Cash Items | 6.36M | -6.17M | 10.10M | 22.65M | 9.01M |
| Change in Net Operating Assets | 7.47M | 25.37M | -53.94M | -82.26M | 21.56M |
| Cash from Operations | 154.22M | 178.47M | 115.38M | 55.79M | 129.43M |
| Capital Expenditure | -950.00K | -3.05M | -1.52M | -2.58M | -3.55M |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -89.47M | 32.53M | -165.97M | -39.46M | -79.14M |
| Cash from Investing | -90.42M | 29.48M | -167.48M | -42.04M | -82.68M |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | -- | 3.59M | 18.56M | 9.48M | -- |
| Repurchase of Common Stock | -3.32M | -250.00M | -- | -- | -489.00K |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | -3.32M | -246.42M | 18.56M | 9.48M | -489.00K |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 60.48M | -38.47M | -33.55M | 23.24M | 46.26M |